A 42-year-old married man with a 10-year history of bipolar I disorder presents to the emergency department after a suicide attempt by pesticide ingestion. His wife reports that over the past 3 months he has been in a depressive episode with prominent hopelessness and anhedonia. He has poor medication adherence and stopped lithium 6 weeks ago. On examination, he appears withdrawn, makes minimal eye contact, and admits to persistent suicidal ideation with a specific plan to harm himself. His past psychiatric history includes two previous suicide attempts (one by hanging 8 years ago, one by overdose 5 years ago). Which of the following is the SINGLE MOST IMPORTANT modifiable risk factor for suicide in this patient that should be addressed urgently?

Explanation

## Suicide Risk Assessment in Bipolar Disorder ### Clinical Context This patient presents with multiple converging high-risk factors: bipolar I disorder, current depressive episode, poor medication adherence, previous suicide attempts, and active suicidal ideation with a plan. ### Key Modifiable Risk Factor **Key Point:** Medication non-adherence and discontinuation of mood stabilizers (particularly lithium) is one of the most critical modifiable risk factors in bipolar disorder. Lithium has the strongest evidence base for suicide prevention in bipolar disorder, with a 5–10-fold reduction in suicide risk compared to other mood stabilizers. **High-Yield:** Lithium's anti-suicidal effect is independent of its mood-stabilizing properties and operates through multiple mechanisms: enhanced serotonergic neurotransmission, neuroprotection, and reduction of impulsivity. ### Why This Answer Restarting lithium and achieving therapeutic levels (0.6–1.2 mEq/L) addresses the most modifiable and evidence-based intervention. The patient's 6-week discontinuation directly precipitated his current crisis. Lithium is the gold standard for suicide prevention in bipolar disorder and should be reintroduced urgently with close monitoring. ### Risk Stratification Table | Risk Factor | Present in This Patient | Significance | | --- | --- | --- | | Bipolar I disorder | Yes | High baseline risk | | Current depressive episode | Yes | Acute risk period | | Previous suicide attempts (≥2) | Yes | Strong predictor of future attempts | | Active suicidal ideation with plan | Yes | Immediate danger | | Recent medication discontinuation | Yes | **Modifiable** | | Male sex | Yes | Higher completion risk | | Middle age (40–50 years) | Yes | Peak risk period in bipolar disorder | ### Management Algorithm ```mermaid flowchart TD A[Suicide attempt + Bipolar I + Off lithium]:::outcome --> B{Medically stable?}:::decision B -->|Yes| C[Admit to psychiatric unit]:::action B -->|No| D[Medical ICU stabilization first]:::action D --> C C --> E[Restart lithium + load if safe]:::action E --> F[Achieve therapeutic level 0.6-1.2]:::action F --> G[Daily monitoring first week]:::action G --> H[Intensive psychotherapy + case management]:::action H --> I[Suicide risk reduced significantly]:::outcome ``` **Clinical Pearl:** Lithium discontinuation is associated with a 20–30-fold increase in suicide risk in the weeks following cessation. Even brief interruptions should be avoided. [cite:Kaplan & Sadock's Synopsis of Psychiatry 11e Ch 8] --- ## Why Other Options Are Incorrect **Admission to general medical ward only:** While medical stabilization is necessary, admission to a general (non-psychiatric) ward without psychiatric care and without restarting mood stabilizers leaves the patient at continued high risk. Psychiatric expertise and medication management are essential. **Psychotherapy alone:** Although psychotherapy (especially dialectical behavior therapy or cognitive-behavioral therapy) is valuable, it is insufficient as monotherapy in acute suicidality with active ideation and plan. Pharmacotherapy with lithium is the evidence-based foundation. **Discharge with outpatient follow-up in 2 weeks:** This is dangerous and inappropriate. A patient with recent suicide attempt, active ideation, a plan, and previous attempts requires inpatient psychiatric admission. Two weeks is far too long to wait for follow-up in this high-risk scenario.